Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
LOS ANGELES, May 25, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX) concerning possible violations of federal securities laws between March 30, 2017 and May 11, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called “Akari’s Coversin matches Soliris in Phase II.” The next day it was announced that the report was withdrawn due to “material inaccuracies.” On May 11, 2017, Akari announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. When this information was announced, Akari shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
